The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro

Asciminib (previously ABL001), which binds the myristate-binding pocket of the Bcr-Abl kinase domain, is in phase I clinical trials as monotherapy and in combination with imatinib, nilotinib and dasatinib for the treatment of patients with refractory CML or Ph+ ALL. Asciminib sensitivity was evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Eadie, Laura N., Saunders, Verity A., Branford, Susan, White, Deborah L., Hughes, Timothy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862588/
https://www.ncbi.nlm.nih.gov/pubmed/29568367
http://dx.doi.org/10.18632/oncotarget.24393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862588/
https://www.ncbi.nlm.nih.gov/pubmed/29568367
http://dx.doi.org/10.18632/oncotarget.24393

Ejemplares similares